Figure 2.

Occurrence of events during follow-up

Kaplan-Meier cumulative estimates of probability of the primary outcome, death, or ventilation support (mechanical ventilation, high-flow oxygen, or non-invasive ventilation; A) and death or mechanical ventilation (B), and overall survival (C) in the sarilumab group as compared with the usual care group. For the primary outcome (death or ventilation support) and death or mechanical ventilation, data are analysed in a Bayesian framework, and median posterior HRs and 90% Crls are presented, together with posterior probabilities of achieving specified effects. Overall survival was analysed in a frequentist framework, so these probabilities are not relevant. Crl=credible interval. HR=hazard ratio.